Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11581MR)

This product GTTS-WQ11581MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Gastric Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, MGAH-22(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11581MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8053MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA h2H12ec
GTTS-WQ3722MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ13867MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-1979
GTTS-WQ3484MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BA1126
GTTS-WQ12609MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NVS250519
GTTS-WQ15668MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VB6-845
GTTS-WQ9303MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMP-321
GTTS-WQ12481MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NN-8226
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW